Buy VYNE by Jul 27, 2026.

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Yarrow Bioscience, Inc. ("Yarrow") pursuant to the Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amended, the "Merger Agreement"). The Cash Dividend, which VYNE estimates will be an aggregate of **$16.5 million, or …